Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinician-Selected FSH Starting Dose and Mature Oocyte Yield in Predicted Poor Responders
Sponsor: American Hospital 2 Kosovo
Summary
This is a single-centre, prospective, non-interventional (observational) cohort study examining the association between the clinician-selected starting dose of follicle-stimulating hormone (FSH) and the yield of mature metaphase II (MII) oocytes in women with predicted poor ovarian response (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number \[POSEIDON\] group 3 or 4) undergoing in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) with a gonadotropin-releasing hormone (GnRH) antagonist protocol. The FSH dose is chosen by the treating physician as part of routine care; the study does not allocate, randomize, or change treatment. The primary outcome is the number of MII oocytes per initiated index cycle. Because dosing is not randomized, analyses are adjusted for measured confounders and address confounding by indication.
Official title: Association of Clinician-Selected FSH Starting Dose With Mature Oocyte Yield in Women With Predicted Poor Ovarian Response: The OPTIMAL-DOSE Prospective Cohort Study
Key Details
Gender
FEMALE
Age Range
18 Years - 42 Years
Study Type
OBSERVATIONAL
Enrollment
160
Start Date
2026-11
Completion Date
2029-08
Last Updated
2026-11-18
Healthy Volunteers
No
Interventions
Follicle-stimulating hormone (FSH)
FSH administered per routine clinical practice; the starting dose is selected by the treating physician (observed exposure, not assigned by the study). Starting dose is analysed continuously (per 75 IU), with categories of 150 IU or less versus more than 150 IU reported descriptively.
Locations (1)
American Hospital Kosova
Pristina, Kosovo